share_log

Aurora Cannabis | 6-K: Report of foreign private issuer (related to financial reporting)

Aurora Cannabis | 6-K: Report of foreign private issuer (related to financial reporting)

极光大麻 | 6-K：外国发行人报告（业绩相关）
美股SEC公告 ·  2024/11/06 20:17

Moomoo AI 已提取核心信息

Aurora Cannabis Inc. reported strong Q2 fiscal 2024 results with net revenue increasing 19% to $164.6 million compared to $137.9 million in Q2 2023. Medical cannabis revenue grew 28% to $108.5 million, while consumer revenue declined to $22.0 million. Gross profit before fair value adjustments improved to $69.3 million from $33.2 million year-over-year.The company achieved net income from continuing operations of $6.5 million, compared to a loss of $19.8 million in the prior year period. Cash and cash equivalents stood at $84.9 million as of September 30, 2024. The company maintained its strong market position in medical cannabis across key international markets including Europe and Australia.Operating expenses increased slightly to $88.2 million from $85.7 million last year. The company recorded an impairment charge of $11.6 million related to assets held for sale in Uruguay as it plans to exit operations there. Management remains focused on operational efficiency and maintaining adequate liquidity through cost reductions and access to its shelf prospectus.
Aurora Cannabis Inc. reported strong Q2 fiscal 2024 results with net revenue increasing 19% to $164.6 million compared to $137.9 million in Q2 2023. Medical cannabis revenue grew 28% to $108.5 million, while consumer revenue declined to $22.0 million. Gross profit before fair value adjustments improved to $69.3 million from $33.2 million year-over-year.The company achieved net income from continuing operations of $6.5 million, compared to a loss of $19.8 million in the prior year period. Cash and cash equivalents stood at $84.9 million as of September 30, 2024. The company maintained its strong market position in medical cannabis across key international markets including Europe and Australia.Operating expenses increased slightly to $88.2 million from $85.7 million last year. The company recorded an impairment charge of $11.6 million related to assets held for sale in Uruguay as it plans to exit operations there. Management remains focused on operational efficiency and maintaining adequate liquidity through cost reductions and access to its shelf prospectus.
Aurora 大麻股公司公布了2024财年第二季度的强劲业绩，净营业收入比2023年第二季度的13790万增加了19%，达到16460万。医疗大麻收入增长28%，达到10850万，而消费收入下降至2200万。毛利润在公允价值调整前从去年的3320万改善至6930万。该公司从持续运营中实现净利润650万，而去年同期则亏损1980万。截至2024年9月30日，现金及现金等价物为8490万。公司在包括欧洲和澳洲在内的主要国际市场中保持了强大的医疗大麻市场地位。营业费用略微上升至8820万，去年为8570万。由于计划退出乌拉圭的业务，公司记录了1160万的资产减值损失。管理层继续专注于运营效率，通过减少成本和获得其柜台发行说明书来维持足够的流动性。
Aurora 大麻股公司公布了2024财年第二季度的强劲业绩，净营业收入比2023年第二季度的13790万增加了19%，达到16460万。医疗大麻收入增长28%，达到10850万，而消费收入下降至2200万。毛利润在公允价值调整前从去年的3320万改善至6930万。该公司从持续运营中实现净利润650万，而去年同期则亏损1980万。截至2024年9月30日，现金及现金等价物为8490万。公司在包括欧洲和澳洲在内的主要国际市场中保持了强大的医疗大麻市场地位。营业费用略微上升至8820万，去年为8570万。由于计划退出乌拉圭的业务，公司记录了1160万的资产减值损失。管理层继续专注于运营效率，通过减少成本和获得其柜台发行说明书来维持足够的流动性。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

独立文件5  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Citius Oncology
    CTOR
    -- 0.930
    脑再生科技
    RGC
    -- 31.880
    正业生物
    ZYBT
    -- 5.380
    Emergent BioSolutions
    EBS
    -- 4.860
    Ironwood医药
    IRWD
    -- 1.470
    解锁完整榜单
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。
    热门讨论
    FOMC维持利率但不确定性高企：美股后市走向如何？
    🎙️讨论 1. 美联储强调政策路径存在“高度不确定性”，你更关注利率预期变化还是经济数据对市场的短期影响？ 2. 若核心通胀维持高位，哪类板块更具交易机会——防御型股票还是科技成长股？ 展开
    联邦公开市场委员会新闻发布会，2025年3月19日